✦ LIBER ✦

Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

✍ Scribed by Jian-Wei Deng; Kwon-Bok Kim; Im-Sook Song; Ji-Hong Shon; Hong-Hao Zhou; Kwang-Hyeon Liu; Jae-Gook Shin

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 164 KB
Volume: 22
Category: Article
ISSN: 0269-3879
DOI: 10.1002/bmc.905

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Determination of the HMG–CoA reductase i

Determination of the HMG–CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry

✍ M. J. Morris; J. D. Gilbert; J. Y.-K. Hsieh; B. K. Matuszewski; H. G. Ramjit; W. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 629 KB

Microextraction in packed syringe (MEPS)

Microextraction in packed syringe (MEPS) for liquid and gas chromatographic applications. Part II—Determination of ropivacaine and its metabolites in human plasma samples using MEPS with liquid chromatography/tandem mass spectrometry

✍ Mohamed Abdel-Rehim; Zeki Altun; Lars Blomberg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract A new technique for sample preparation on‐line with liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay was developed. Microextraction in a packed syringe (MEPS) is a new miniaturized, solid‐phase extraction technique that can be connected on‐line to gas or liquid chromato

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti